NewLimit

📍 South San Francisco, United States🗓 Founded 2022👥 63 employees💰 Last funded May 2025
Biotechnology Research🌐 newlimit.com
Website LinkedIn
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale. All correspondence from NewLimit will come from an @NewLimit.com email address.
4
Total investors
1
Early stage
3
Mid stage
0
Late stage
2022
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
4
Investor activity2021–2025 · investors recorded per year
2021120253
Recent (last 2y)Earlier
Frequently asked questions
Who invested in NewLimit?
NewLimit has 4 investors on record on gritt.io, including 1 early-stage backers, 3 mid-stage.
When did NewLimit last raise funding?
The most recent investment in NewLimit recorded on gritt.io was in May 2025.
When was NewLimit founded?
NewLimit was founded in 2022.
What industry is NewLimit in?
NewLimit operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is NewLimit based?
NewLimit is headquartered in South San Francisco, United States.